The FDA has classified a recall of a thyroid medication as Class I — its highest-risk category — after one lot of Vitruvias Therapeutics’ Thyroid Tablets, USP 30 mg was found to be superpotent, meaning the tablets contain more active thyroid hormone than the label states.
Key Takeaways
- The affected product is Thyroid Tablets, USP 30 mg (1/2 grain), lot number 504950, NDC 69680-166-00, expiring September 30, 2026, made by Vitruvias Therapeutics of Auburn, Alabama.
- The FDA’s concern is too much thyroid hormone per tablet, which can cause hyperthyroid-like symptoms: rapid heart rate, chest pain, heart rhythm disturbances, weight loss, heat intolerance, nervousness, and muscle weakness.
- The company voluntarily recalled the lot on August 21, 2026; the FDA elevated it to Class I, its most serious classification, on September 22, 2026. No adverse events had been reported as of the recall notice.
- About 3,655 units were distributed nationwide, with roughly 1,955 actually sold to patients, over a distribution window from January 31 to September 30, 2025.
- If your bottle matches this lot, contact your prescribing doctor or pharmacist before making any changes — the FDA’s own guidance is not to stop taking thyroid medication without medical supervision, since abruptly stopping thyroid treatment carries its own separate risks.
Why this recall was elevated to Class I
The FDA reserves Class I, its most serious classification, for situations where there’s a reasonable probability that using the affected product could cause serious health consequences or death. In this case, that risk comes from the opposite problem you might expect with a “bad batch” — not too little medication, but too much. Thyroid hormone medications like this one are dosed precisely because both too little and too much cause real harm; a superpotent tablet can push someone into symptoms resembling hyperthyroidism, including a racing or irregular heartbeat, chest pain, and cardiovascular strain. The FDA specifically flagged elderly patients, pregnant women, and infants as facing the greatest risk from excess thyroid hormone exposure.
What to actually do if you take this medication
Check your bottle for lot number 504950 and NDC 69680-166-00. If it matches, the right move is to contact your prescribing doctor or pharmacist — not to simply stop taking it on your own. This is worth being precise about, since thyroid medication carries risk in both directions: suddenly stopping it can cause its own withdrawal-like symptoms as thyroid hormone levels drop, on top of whatever symptoms the excess dosing may have already caused. A doctor or pharmacist can confirm whether your bottle is affected and arrange a replacement prescription from an unaffected lot.
The bigger picture
This is one of several thyroid medication recalls in recent years — both superpotency and subpotency issues have affected different manufacturers’ thyroid products before, a reminder that these are narrow-therapeutic-index drugs where small formulation errors can have outsized effects on patients. As of the recall notice, Vitruvias Therapeutics had not received any reports of adverse events tied to this specific lot, but the Class I classification reflects the seriousness of the risk if a patient did receive an affected superpotent tablet, not confirmation that harm has already occurred.